Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The calcitonin gene-related peptide (CGRP) pathway is important in migraine pathophysiology. We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in patients with chronic migraine.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Neurol

Title: The Lancet. Neurology

Publisher: Elsevier BV

ISSN (Electronic): 1474-4465

ISSN (Print): 1474-4422

Publication date (Electronic): Jun 2017

Volume: 16

Issue: 6

Affiliations

[1 ] Geisel School of Medicine at Dartmouth, Hanover, NH, USA. Electronic address: stewart.j.tepper@dartmouth.edu.

[2 ] Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Copenhagen, Denmark.

[3 ] Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.

[4 ] Nashville Neuroscience Group and Vanderbilt University Department of Neurology, Nashville, TN, USA.

[5 ] DADO MEDICAL sro, Prague Headache Center, Prague, Czech Republic.

[6 ] Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.

[7 ] Premiere Research Institute, Nova Southeastern University, West Palm Beach, FL, USA.

[8 ] Global Biostatistical Science, Amgen Inc, Thousand Oaks, CA, USA.

[9 ] Global Development, Amgen Inc, Thousand Oaks, CA, USA.

Article

Publisher Item ID: S1474-4422(17)30083-2

DOI: 10.1016/S1474-4422(17)30083-2

PubMed ID: 28460892

SO-VID: 94c03e31-94cc-4650-ba49-35c94da61703

History

Data availability:

Comments

Comment on this article

scite_

Cited by 293

See all cited by